Nanoparticle-based topical ophthalmic formulations for sustained celecoxib release

Journal of Pharmaceutical Sciences

Volumn 102, Issue 3, 2013, Pages 1036-1053

  Ibrahim, Mohammed Mostafa ^a,b   Abd Elgawad, Abd Elgawad Helmy ^b   Soliman, Osama Abd Elazeem ^b   Jablonski, Monica M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Biocompatibility; Celecoxib; Controlled release; Cytotoxicity; l lactide co glycolide); Nanoparticles; Ophthalmic; Poly(d; Poly(l lactide); Poly caprolactone

Indexed keywords

CELECOXIB; EYE DROPS; NANOPARTICLE; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIDE;

ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DIFFUSION; DRUG SYNTHESIS; IN VITRO STUDY; NANOENCAPSULATION; PARTICLE SIZE; PATIENT COMPLIANCE; PH; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TOPICAL TREATMENT; VISCOSITY; ZETA POTENTIAL;

EID: 84878128492     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23417     Document Type: Article

References (55)

1. Schalnus R. 2003. Topical non-steroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 217:89-98.
2. Kern TS, Miller CM, Du Y, Zheng L, Mohr S, Ball SL, Kim M, Jamison JA, Bingaman DP. 2007. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 56:373-379.
3. Maloney SC, Fernandes BF, Castiglione E, Antecka E, Martins C, Marshall JC, Di-Cesare S, Logan P, Burnier MN Jr. 2009. Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients. Retina 29:176-180.
4. Frota AC, Odashiro AN, Pereira PR, Fernandes BF, Godeiro KD, Filho JP, Burnier MN Jr. 2007. Immuno-histochemical expression of COX-2 and c-kit in metastatic uveal melanoma. Can J Ophthalmol 42:145-146.
5. Needleman P, Isakson PC. 1997. The discovery and function of COX-2. J Rheumatol Suppl 49:6-8.
6. Kim SJ, Flach AJ, Jampol LM. 2010. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 55:108-133.
7. Johnson EI, Dunlop ME, Larkins RG. 1999. Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Curr Eye Res 18:79-82.
8. Tong CT, Howard SA, Shah HR, Van Quill KR, Lin ET, Grossniklaus HE, O'Brien JM. 2005. Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma. Br J Ophthalmol 89:1217-1220.
9. Bauer AM, Fiehn C, Becker MD. 2005. Celecoxib, a selective inhibitor of cyclooxygenase 2 for therapy of diffuse anterior scleritis. Am J Ophthalmol 139:1086-1089.
10. Ayalasomayajula SP, Kompella UB. 2004. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res 21:1797-1804.
11. Amrite AC, Ayalasomayajula SP, Cheruvu NPS, Kompella UB. 2006. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophth Vis Sci 47:1149-1160.
12. Ayalasomayajula SP, Kompella UB. 2005. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol 511:191-198.
13. Cheruvu NPS, Amrite AC, Kompella UB. 2008. Effect of eye pigmentation on transscleral drug delivery. Invest Ophth Vis Sci 49:333-341.
14. Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. 1998. Ophthalmic drug delivery systems: Recent advances. Prog Retinal Eye Res 17:33-58.
15. Smolin G, Okumoto M, Feiler S, Condon D. 1981. Idoxuridine-liposome therapy for herpes simplex keratitis. Am J Ophthalmol 91:220-225.
16. Losa C, Calvo P, Castro E, Vila-Jato JL, Alonso MJ. 1991. Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles. J Pharm Pharmacol 43:548-552.
17. Losa C, Marchal-Heussler L, Orallo F, Vila-Jato JL, Alonso MJ. 1993. Design of new formulations for topical ocular administration: Polymeric nanocapsules containing metipranolol. Pharm Res 10:80-87.
18. Nair LS, Laurencin CT. 2007. Biodegradable polymers as biomaterials. Prog Polym Sci 32:762-798.
19. Kumari A, Yadav SK, Yadav SC. 2010. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surfaces B: Bioenterfaces 75:1-18.
20. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. 1993. Preparation of biodegradable nanospheres of water soluble and insoluble drugs with d, l-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Control Release 25:89-98.
21. Liu Z, Li J, Nie S, Liu H, Ding P, Pan W. 2006. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm 315:12-17.
22. Kuzma JW, Bohnenblust SE. 2005. Basic statistics for the health sciences. 5th ed. New York: McGraw-Hill Education.
23. Zhang Y, Zhuo R. 2006. Synthesis, characterization, and in vitro 5-fu release behavior of poly(2, 2-dimethyltrimethylene carbonate)-poly(ethylene glycol)-poly(2, 2-dimethyltrimethylene carbonate) nanoparticles. J Biomed Mater Res A 76:674-680.
24. Mainardes RM, Evangelista RC. 2005. PLGA nanoparticles containing praziquantel: Effect of formulation variables on size distribution. Int J Pharm 290:137-144.
25. Mittal G, Sahana DK, Bhardwaj V, Kumar MNVR. 2007. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release 119:77-85.
26. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. 2002. Residual polyvinyl alcohol associated with poly (d, l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 82:105-114.
27. Mao S, Xu J, Cai C, Germershaus O, Schaper A, Kissel T. 2007. Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres. Int J Pharm 334:137-148.
28. Redhead HM, Davis SS, Illum L. 2001. Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterization and in vivo evaluation. J Control Release 70:353-363.
29. Scholes PD, Coombes AGA, Illum L, Davis SS, Watts JF, Ustariz C, Vert M, Davies MC. 1999. Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. J Control Release 59:261-278.
30. Tan Q, Liu W, Guo C, Zhai G. 2011. Preparation and evaluation of quercetin loaded lecithin-chitosan nanoparticles for topical delivery. Int J Nanomed 6:1621-1630.
31. El-Shabouri MH. 2002. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm 249:101-108.
32. Tripathi A, Gupta R, Saraf SA. 2010. PLGA nanoparticles of anti-tubercular drug: Drug loading and release studies of a water in-soluble drug. Int J Pharm Tech Res 2:2116-2123.
33. Yadav KS, Sawant KK. 2010. Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles. AAPS Pharm Sci Tech 11:1456-1465.
34. Hafner A, Durrigl M, Pepic I, Filipovic-Grcic J. 2011. Short- and long-term stability of lyophilised melatonin-loaded lecithin/chitosan nanoparticles. Chem Pharm Bull 59:1117-1123.
35. Sonaje K, Chen YJ, Chen HL, Wey SP, Juang JH, Nguyen HN, Hsu CW, Lin KJ, Sung HW. 2010. Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 31:3384-3394.
36. De Chasteigner S, Cavé G, Fessi H, Devissaguet JP, Puisieux F. 1996. Freeze-drying of itraconazole-loaded nanosphere suspensions: A feasibility study. Drug Dev Res 38:116-124.
37. Seijo B, Fattal E, Roblot-Treupel L, Couvreur P. 1990. Design of nanoparticles of less than 50 nm diameter: Preparation, characterization and drug loading. Int J Pharm 62:1-7.
38. Scholes PD, Coombes AGA, Illum L, Davis SS, Vert M, Davies MC. 1993. The preparation of sub-200 nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery. J Control Release 25:145-153.
39. Kim T, Jeong Y, Jin S, Pei J, Jung T, Moon K, Kim I, Kang S, Jung S. 2011. Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells. Int J Nanomed 6:2621-2631.
40. USP29-NF24, "The United States Pharmacopeia", 29th, 2005. Pharmaceutical dosage forms, ophthalmic preparation and uniformity of dosage units chapters, United States Pharmacopeial Convention, Inc. Maryland (online version) http://www.pharmacopeia.cn/.
41. Wu H, Lui Z, Peng J, Li L, Li N, Li J, Pan H. 2011. Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery. Int J Pharm 410:31-40.
42. Hammer ME, Burch TG. 1984. viscous corneal protection by sodium hyaluronate, chondroitin sulfate, and methylcellulose. Invest Ophth Vis Sci 25:1329-1332.
43. Lin H, Sung KC. 2000. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release 69:379-388.
44. Huang YY, Chung TW, Tzeng TW. 1999. A method using biodegradable polylactides/polyethylene glycol for drug release with reduced initial burst. Int J Pharm 182:93-100.
45. Garcia-Fuentes M, Torres D, Alonso MJ. 2005. New surface modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm 296:122-132.
46. Budhian A, Siegel SJ, Winey KI. 2008. Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. Int J Pharm 346:151-159.
47. Leroux JC, Allemann E, Jaeghere FD, Doelker E, Gurny R. 1996. Biodegradable nanoparticles-from sustained release formulations to improved site specific drug delivery. J Control Release 39:339-350.
48. Budai L, Hajdu M, Budai M, Grof P, Beni S, Noszal B, Klebovich I, Antal I. 2007. Gels and liposomes in optimized ocular drug delivery: Studies on ciprofloxacin formulations. Int J Pharm 343:34-40.
49. Tamizharasi S, Rathi JC, Rathi V, 2008. Formulation and evaluation of Pentoxifylline-loaded poly(é-caprolactone) microspheres. Ind J Pharm Sci 70:333-335.
50. Korsmeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA. 1983. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 15:25-35.
51. Dash S, Murthy PN, Nath L, Chowdhury P. 2010. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm Drug Res 67:217-223.
52. German EJ, Hurst MA, Wood D. 1999. Reliability of drop size from multi-dose eye drop bottles: Is it cause for concern? Eye (Lond) 13:93-100.
53. Vandervoort J, Ludwig A. 2002. Biocompatible stabilizers in the preparation of PLGA nanoparticles: A factorial design. Int J Pharm 238:77-92.
54. De S, Robinson D. 2003. Polymer relationships during preparation of chitosan-alginate and poly-l-lysine-alginate nanospheres. J Control Release 89:101-112.
55. Alonso MJ. 2004. Nanomedicines for overcoming biological barriers. Biomed Pharmacoth 58:68-72.